549534-58-9 Usage
General Description
The chemical "(2R,4S)-4-Alloc-amino-1-Fmoc-Pyrrolidine-2-carboxylic acid" is a compound with a pyrrolidine ring structure and an amino acid functionality. The "(2R,4S)" designation indicates the stereochemistry of the molecule, specifically the orientation of the substituents around the chiral centers. The "Alloc" group serves as a protecting group for the amine functionality, while the "Fmoc" group is a common protecting group for the carboxylic acid functionality. (2R,4S)-4-Alloc-amino-1-Fmoc-Pyrrolidine-2-carboxylic acid likely has applications in peptide synthesis and organic chemistry, as its structure suggests it can participate in peptide bond formation and other chemical reactions involving amino acids. Overall, "(2R,4S)-4-Alloc-amino-1-Fmoc-Pyrrolidine-2-carboxylic acid" is a complex molecule with potential utility in the field of chemical synthesis.
Check Digit Verification of cas no
The CAS Registry Mumber 549534-58-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 5,4,9,5,3 and 4 respectively; the second part has 2 digits, 5 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 549534-58:
(8*5)+(7*4)+(6*9)+(5*5)+(4*3)+(3*4)+(2*5)+(1*8)=189
189 % 10 = 9
So 549534-58-9 is a valid CAS Registry Number.
549534-58-9Relevant articles and documents
Structure - Activity relationship studies of targeting ligands against breast cancer cells
Yao, Nianhuan,Xiao, Wenwu,Meza, Leah,Tseng, Harry,Chuck, Mathida,Lam, Kit S.
supporting information; experimental part, p. 6744 - 6751 (2010/04/04)
A series of LXY3 (1) analogues were designed and synthesized. Their binding affinity was demonstrated using MDA-MB-231 breast cancer cells adherence inhibition assay. Further structure-activity relationship was obtained. Analogue 29 was discovered to have 3.5-fold increase of the binding affinity. Fluorescent microscopy and in vivo and ex vivo imaging studies demonstrated that 29 is an efficient in vivo targeting agent against α3 integrin of MDA-MB-231 breast tumor xenograft implant. 2009 American Chemical Society.